TABLE 3.

Distribution of clinical isolates by PGG

Study approachIsolates includedResistance patternNo. of isolates in PGG/total no. of isolates (%)a
PGG-1PGG-2PGG-3
Counting all isolatesAllMono-INHr31/68 (46)31/68 (46)6/68 (8)
AllINHr + resistance to ≥1 drug52/227 (23)142/227 (62)33/227 (15)
katG315 mutantsMono-INHr17/32 (53)14/32 (44)1/32 (3)
katG315 mutantsINHr + resistance to ≥1 drug38/143 (27)90/143 (63)15/143 (10)
Counting one isolate per clusterbAllMono-INHr30/65 (46)29/65 (45)6/65 (9)
AllINHr + resistance to ≥1 drug41/192 (21)122/192 (64)29/192 (15)
katG315 mutantsMono-INHr17/31 (55)13/31 (42)1/31 (3)
katG315 mutantsINHr resistance to ≥1 drug27/110 (25)71/110 (64)12/110 (11)
  • a Results based on 68/101(67%) and 227/297(76%) mono-INHr isolates and MDR isolates, respectively.

  • b Results using all unique isolates plus one isolate from each cluster. In cases where a cluster contained isolates with different drug susceptibility profiles and/or mutations, each variation was counted as a new cluster.